BioSpace News Archive

Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) (“Acerus” or the “Company”) today announced that it has received a Notice of Deficiency (“NOD”) for its avanafil New Drug Submission (NDS). Health Canada has requested the provision of additional quality information related to the avanafil drug substance in alignment with Intern

- Ongoing Phase 1 dose escalation and expansion study with CUE-101 as a monotherapy in post first-line recurrent/metastatic HNSCC patients to be amended to include combination of CUE-101 with standard of care KEYTRUDA as first-line therapy - Preliminary data from early patient cohorts in the current ongoing CUE-101 monotherapy Phase 1 trial in post first-line recurrent/metastatic HNSCC patients demonstrates tolerability and drug exposure, and provides confidence for drug activity consist

POXEL SA announced that the Universal Registration Document for the year ended December 31, 2019 has been filed with the stock market regulator in France, Autorité des Marchés Financiers.

This investment brings the total financing by Sofinnova Partners to €25 million over the past six months

GTX medical BV announced the appointment of John Murphy, Ph.D., as Chief Technology Officer. Dr. Murphy joins the company with over twenty years of experience in Class I, II, and III medical devices and implantables and has been instrumental in bringing numerous new devices to commercialization.

Portable ventilators are used to deliver oxygen to patients when required. These ventilators are used in hospitals and day care centers for continuous oxygen supply when a COPD patient is unconsciousness or when there is discomfort due to breathing problems.

Transparency Market Research has published a new report titled, ‘Hospital acquired disease testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

The rising demand for disposable gloves in cleanroom environments in various industries, notably in food and beverages, aerospace, healthcare and pharmaceuticals, and semiconductors, is driven by the need for prevention of cross-contamination across processes and products.

- First off-the-shelf AdenoVerse™ immunotherapy to enter the clinic - - Immunotherapy designed to activate the immune system to recognize and target HPV+ solid tumors -

Company is Well-Positioned for Success as it Emerges from Chapter 11 In Partnership with Deerfield, Plans for Growth are Announced NEW YORK--( BUSINESS WIRE )-- Commercial-stage antibiotics company Melinta Therapeutics (“Melinta”) and healthcare investment firm Deerfield Management Company, L.P. (“Deerfield”), announced today that Melinta has successfully completed its financial restructuring and has emerged from Chapter 11. In accordanc